PARP Inhibitor

Zai Lab announced that VYVGART, NUZYRA and ZEJULA have been renewed on China’s 2025 NRDL, expanding access for generalized myasthenia gravis, community‑acquired pneumonia/ABSSSI, and maintenance therapy in platinum‑sensitive ovarian cancer. The renewals underscore clinical value, lower patient costs, and position Zai Lab for growth in immunology, infectious disease and oncology, with projected multi‑year revenue uplift and an 18‑22% CAGR through 2028.

Corcept Therapeutics presented Phase 3 ROSELLA trial data at ESMO 2025, showing relacorilant plus nab-paclitaxel significantly improved progression-free and overall survival in platinum-resistant ovarian cancer patients, including those progressing on PARP inhibitors. The combination also demonstrated a favorable safety profile. Corcept is expanding the Phase 2 BELLA trial to include platinum-sensitive ovarian and endometrial cancer arms, with initial results expected in late 2026. The FDA has granted relacorilant priority review for platinum-resistant ovarian cancer with a PDUFA date of July 11, 2026.